NEWARK, Del, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The Cancer Biopsy market revenues were estimated at US$ 22.2 Billion in 2022 and is anticipated to grow at a CAGR of 18% from 2023-2033, according to a recently published Future Market Insights report. By the end of 2033, the market is expected to reach US$ 131.4 Billion.
The increasing elderly populace, along with the rise in instances of cancer diagnoses, is fueling growth in the cancer clinical market. Also, the effective and less costly use of liquid biopsy procedures and increasing biopsy appointees are all expected to impact the market growth.
Some of today's prominent procedures in medical diagnosis include endoscopic, arthroscopic, bone marrow, skin, needle, and surgical biopsies. Needle biopsies are regarded as a trusted method for the early detection of patients suffering from these methods. However, fine-needle aspiration needle biopsies, which have been found to be less invasive and faster, are aiding the increase in popularity of the slice.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16508
The IARC estimates that by 2020 the worldwide burden of disease due to cancer is projected to be 19.3 million cases and 9.96 million deaths worldwide. A liquid biopsy entails reduced expense, earlier prognosis, therapy surveillance, identification of tumor heterogeneity, acquired drug resistance, and patient comfort compared to conventional diagnostic tools for handling cancer.
Competitive Analysis
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
Key recent developments of key players in the Cancer Biopsy Market are as follows:
- In March 2021, in Russia, KIllumina, Inc. received medical device approval for their NextSeq 550Dx platform and related reagent kits. Prior to this registration, the MiSeq Dx had already been approved as a medical device.
- In March 2021, Autopsy with Quick-Core IZI Medical Products introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company's patented semi-automatic method.
Competitive Landscape
Key companies are helping to drive market expansion by diversifying their diagnostics portfolios and increasing the adoption of their own biopsy tools.
- In March 2021, In Russia, KIllumina, Inc. has received medical device approval for their NextSeq 550Dx platform and related reagent kits. Prior to this registration, the MiSeq Dx had already been approved as a medical device.
- In March 2021, Autopsy with a Quick-Core IZI Medical Products has introduced a system for soft tissue biopsy procedures. This fully automated product is based on Quick-Core, the company's patented semi-automatic method.
- In April 2021, Plasma-SeqSensei liquid biopsy research use only (RUO) kits were introduced in EMEA by Sysmex Europe GmbH and Sysmex Inostics GmbH.
View Complete Report@ https://www.futuremarketinsights.com/reports/cancer-biopsy-market
Market Segments Covered in Cancer Biopsy Industry Analysis
By Type:
- Tissue Biopsies
- Needle Biopsies
- Surgical Biopsies
- Liquid Biopsies
- Other Types
By Product Type:
- Instruments
- Kits and Consumables
- Services
By Application:
- Breast Cancer
- Colorectal Cancer
- Cervical Cancers
- Lung Cancers
- Prostate Cancers
- Skin Cancers
- Blood Cancers
- Kidney Cancers
- Liver Cancers
- Pancreatic Cancers
- Ovarian Cancers
- Other Applications
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16508
More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Cancer Biopsy Market, presenting historical market data (2018-2022) and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of by Type (Tissue Biopsies, Liquid biopsies, Other Types), by Product Type (Instruments, Kits and Consumables, Services), by Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Other Applications) across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Future Market Insights Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Billion)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16508
Have a Look at Related Reports of Healthcare domain
Vascular Ulcer Treatment Market Size: The global vascular ulcer treatment demand is expected to rise at a CAGR of 4.7%. The market revenue is likely to be valued at US$ 2,638.6 million in 2022, and exhibit a revenue growth of US$ 4,380 million by 2032.
Immunoassay Market Share: The global immunoassay market is expected to be worth USD 45.78 billion by 2032, growing at a CAGR of 5% from its current value of USD 29.51 billion in 2022.
Vaginal Specula Market Growth: The global vaginal specula market size is anticipated to expand from US$ 908.4 million in 2022 and is projected to reach US$ 1214.4 million by 2032, indexing a CAGR of 2.7% by the end of the forecast period.
3D Printed Maxillofacial Implants Market Demand: The global 3-D printed maxillofacial implants market is expected to display a CAGR of 8% while amassing a market value worth US$ 1,100.4 Million in 2032, against US$ 474.2 Million in 2022.
3D Printed Drugs Market Trends: The worldwide 3D printed drugs market is estimated to generate a market value of US$ 307.54 Million in 2022 and a market value of US$ 742.88 Million by 2032, with a CAGR of 9.2% from 2022 to 2032.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
